Skip to main content
SpringerLink
Log in

Follicular Lymphomas: Morphology, Prognostic Factors and Treatment

  • Conference paper
Interferons

Abstract

Meaningful discussion of therapy of a disease requires a precise definition of the pathologic entity needing therapy. This requirement is only partially fulfilled for the non-Hodgkin’s lymphomas (NHL). Classification of these malignancies is particularly difficult at present as molecular biologists, cytogeneticists, immunologists, histopathologists and clinicians all strive to increase diagnostic precision with the NHLs. This article concentrates on the low-grade lymphomas which are subdivided differently in the two most commonly used histologic classifications for lymphomas—the Working Formulation for Clinical Usage [1, 2] and the Kiel Classification [3, 4]. Although these classification systems allow differentiation of lymphoma subtypes by histology [5], classification according to prognosis is more difficult since the final outcome may change with treatment. These socalled low-grade lymphomas can be divided into two broad categories, follicular lymphomas and diffuse B or T small-cell lymphomas (Table 1). The clinical aggressiveness associated with the two categories of lymphomas, as well as the outcome of these patients, is variable. In some cases the lymphomas have very low clinical aggressiveness and patients have a long survival time irrespective of the type of treatment. In other cases, the lymphomas are much more aggressive, with patients having a low response rate to treatment, a short progression-free survival and short overall survival.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. The Non-Hodgkin’s Lymphoma Pathologic Classification Project (1982) National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas. Summary and description of a Working Formulation for Clinical Usage. Cancer 49: 2112–2135

    Article  Google Scholar 

  2. Simon R, Durrleman S, Hoppe RT et al (1988) The Non-Hodgkin Lymphoma Pathologic Classification Project. Long-term follow-up of 1153 patients with non-Hodgkin lymphomas. Ann Intern Med 109: 939–945

    PubMed  CAS  Google Scholar 

  3. Lennert K, Mohri N, Stein H et al (1975) The histopathology of malignant lymphoma. Br J Haematol 31: 193–203

    Article  Google Scholar 

  4. Lennert K, Feller AC (1990) Histopathologic der Non-Hodgkin Lymphome (nach der aktualisierten Kiel-Klassifikation). Springer, Berlin Heidelberg New York

    Google Scholar 

  5. Harris NL (1993) The pathology of lymphomas. A practical approach to diagnosis and classification. Surg Oncol Clin NA 2: 167–206

    Google Scholar 

  6. Mann R, Berard C (1982) Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method. Hematol Oncol 1: 187–195

    Article  Google Scholar 

  7. Lennert K (1978) Malignant lymphomas other than Hodgkin’s disease. Springer, Berlin Heidelberg New York

    Google Scholar 

  8. Batata A, Shen B (1992) Relationship between chronic lymphocytic leukemia and small lymphocytic lymphoma: a comparative study of membrane phenotypes in 270 cases. Cancer 70: 625–632

    Article  PubMed  CAS  Google Scholar 

  9. Ben-Ezra J, Burke JS, Schwartz WG et al (1989) Small lymphocytic lymphoma: a clinicopathologic analysis of 268 cases. Blood 73: 579–587

    PubMed  CAS  Google Scholar 

  10. Sundeen JT, Longo DL, Jaffe ES (1992) CD5 expression in B-cell small lymphocytic malignancies: correlations with clinical presentation and sites of disease. Am J Surg Pathol 16: 130–137

    Article  PubMed  CAS  Google Scholar 

  11. Berger F, Felman P, Sonet A et al (1994) Diffuse small B-cell lymphomas: an heterogeneous group of patients with distinct clinical features and outcome. Blood 83: 2829–2835

    PubMed  CAS  Google Scholar 

  12. Patsouris E, Noel H, Lennert K (1990) Lymphoplasmacytic/lymphoplasmacytoid immunocytoma with a high content of epithelioid cells. Histologic and immunohistochemical findings. Am J Surg Pathol 14: 660–670

    Article  PubMed  CAS  Google Scholar 

  13. Pugh WC, Manning JT, Butler JJ (1988) Paraimmunoblastic variant of small lymphocytic/lymphoma/leukemia. Am J Surg Pathol 12: 907–917

    Article  PubMed  CAS  Google Scholar 

  14. Banks PM, Chan J, Cleary ML et al (1992) Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 16: 637–640

    Article  PubMed  CAS  Google Scholar 

  15. Raffeld M, Jaffe ES (1991) Bcl-1, t (11;14), and mantle cell-derived lymphomas. Blood 78: 259–263

    PubMed  CAS  Google Scholar 

  16. Weisenburger DD, Nathwani BN, Diamond LW et al (1981) Malignant lymphoma, intermediate lymphocytic type: a clinicopathologic study of 42 cases. Cancer 48: 1415–1425

    Article  PubMed  CAS  Google Scholar 

  17. Perry DA, Bast MA, Armitage JO et al (1990) Diffuse intermediate lymphocytic lymphoma: a clinicopathologic study and comparison with small lymphocytic lymphoma and diffuse small cleaved cell lymphoma. Cancer 66: 1995–2000

    Article  PubMed  CAS  Google Scholar 

  18. Isaacson P (1984) Extranodal malignant lymphoma arising from mucosa-associated lymphoid tissue. Cancer 53: 2515–2524

    Article  PubMed  CAS  Google Scholar 

  19. Pelstring RJ, Essell JH, Kurtin PJ et al (1991) Diversity of organ site involvement among malignant lymphomas of mucosa-associated tissues. Am J Clin Pathol 96: 738–745

    PubMed  CAS  Google Scholar 

  20. Harris NL (1991) Extranodal lymphoid infiltrates and mucosa-associated lymphoid tissue (MALT). A unifying concept. Am J Surg Pathol 15: 879–884

    Article  PubMed  CAS  Google Scholar 

  21. Isaacson PG (1992) Gastrointestinal lymphomas and lymphoid hyperplasias. In: Knowles DM (ed) Neoplastic hematology. Williams and Wilkins, Baltimore, 953–978

    Google Scholar 

  22. Cogliatti SB, Lennert K, Hansmann ML et al (1990) Monocytoid-B cell lymphoma: clinical and prognostic features of 21 patients. J Clin Pathol 43: 619–625

    Article  PubMed  CAS  Google Scholar 

  23. Sheibani K, Sohn CC, Burke JS et al (1986) Monocytoid B-cell lymphoma. A novel B-cell neoplasm. Am J Pathol 124: 310–318

    PubMed  CAS  Google Scholar 

  24. Nathwani BN, Mohrmann RL, Brynes RK et al (1992) Monocytoid B-cell lymphomas. An assessment of diagnostic criteria and a perspective on histogenesis. Hum Pathol 23: 1061–1071

    Article  PubMed  CAS  Google Scholar 

  25. Sheibani K, Burke JS, Swartz WG et al (1988) Monocytoid B-cell lymphoma. Clinicopathologic study of 21 cases of a unique type of low-grade lymphoma. Cancer 62: 1531–1538

    Article  PubMed  CAS  Google Scholar 

  26. Melo J, Hegde U, Parreira A et al (1987) Splenic B-cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens. J Clin Pathol 40: 642–651

    Article  PubMed  CAS  Google Scholar 

  27. Carbone A, Pinto A, Gloghini A et al (1990) Report of an unusual small lymphocytic B-cell lymphoma selectively involving the B-zone of lymph node. Cancer 66: 302–312

    Article  PubMed  CAS  Google Scholar 

  28. Schmid C, Kirkham N, Diss T et al (1992) Splenic marginal zone cell lymphoma. Am J Surg Pathol 16: 455–466

    Article  PubMed  CAS  Google Scholar 

  29. Nathwani BN, Metter GE, Miller TP et al (1981) What should be the morphologic criteria for the subdivision of follicular lymphomas? Blood 68: 837–845

    Google Scholar 

  30. Dardick I, Caldwell DR (1986) Follicular center cell lymphoma. Morphologic data relating to observer reproducibility. Cancer 58: 2477–2484

    Article  PubMed  CAS  Google Scholar 

  31. Molenaar WM, Bartels H, Koudstaal J (1985) The significance of the number of centroblasts in centroblastic/centrocy tic lymphomas. A long term study in a large group of patients. Virchows Arch Pathol Anat A 405: 325–331

    Article  CAS  Google Scholar 

  32. Ezdinli EZ, Costello WG, Kucuk O et al (1987) Effect of the degree of nodularity on the survival of patients with nodular lymphomas. J Clin Oncol 5: 413–418

    PubMed  CAS  Google Scholar 

  33. Rudders RA, Kaddis M, DeLellis RA et al (1979) Nodular non-Hodgkin’s lymphoma. Factors influencing prognosis and indications for aggressive treatment. Cancer 43: 1643–1651

    Article  PubMed  CAS  Google Scholar 

  34. Anderson T, DeVita VT, Simon RM et al (1982) Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the National Cancer Institute. Cancer 50: 2708–2721

    Article  PubMed  CAS  Google Scholar 

  35. Bastion Y, Berger F, Bryon PA et al (1991) Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 9: 123–129

    Google Scholar 

  36. Anderson JR, Vose JM, Bierman PJ et al (1993) Clinical features and prognosis of follicular large-cell lymphoma. A report from the Nebraska Lymphoma Study Group. J Clin Oncol 11: 218–224

    PubMed  CAS  Google Scholar 

  37. Akerman M, Brandt L, Johnson A et al (1987) Mitotic activity in non-Hodgkin’s lymphoma. Relation to the Kiel classification and to prognosis. Br J Cancer 55: 219–223

    Article  PubMed  CAS  Google Scholar 

  38. Macartney JC, Camplejohn RS (1990) DNA flow cytometry of non-Hodgkin’s lymphomas. Eur J Cancer 26: 635–637

    Article  PubMed  CAS  Google Scholar 

  39. Holte H, Davies CD, Beiske K et al (1989) Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma. Int J Cancer 44: 975–980

    Article  PubMed  CAS  Google Scholar 

  40. Woba BA, Knowles DM (1979) Nodular lymphocytic lymphoma eventuating into diffuse histiocytic lymphoma. Immunoperoxidase demonstration of monoclonality. Cancer 43: 303–307

    Article  Google Scholar 

  41. de Jong D, Voetdijk BMH, Beverstock GC et al (1988) Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N Engl J Med 318: 1373–1377

    Article  PubMed  Google Scholar 

  42. Lee JT, Innes DJ, Williams ME (1989) Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin’s lymphoma. J Clin Invest 84: 1454–1459

    Article  PubMed  CAS  Google Scholar 

  43. Shin SS, Benezra J, Burke JS et al (1993) Reed-Sternberg-like cells in low-grade lymphomas are transformed neoplastic cells of B-cell lineage. Am J Clin Pathol 99: 658–662

    PubMed  CAS  Google Scholar 

  44. Cotter FE (1990) The role of the bcl-2 gene in lymphoma. Br J Haematol 75: 449–453

    Article  PubMed  CAS  Google Scholar 

  45. Yunis JJ, Frizzerà G, Oken MM et al (1987) Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N Engl J Med 316: 79–84

    Article  PubMed  CAS  Google Scholar 

  46. Haldar S, Reed JC, Beatty C et al (1990) Role of bcl-2 in growth factor triggered signal transduction. Cancer Res 50: 7399–7401

    PubMed  CAS  Google Scholar 

  47. Magrath I (1992) Molecular basis of lymphomagenesis. Cancer Res 52: S5529–S5540

    Google Scholar 

  48. Offit K, Chaganti RSK (1991) Chromosomal aberrations in non-Hodgkin’s lymphoma: biologic and clinical correlations. Hematol/Oncol Clin NA 5: 853–869

    CAS  Google Scholar 

  49. Horning SJ, Rosenberg SA (1984) The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med 311: 1471–1475

    Article  PubMed  CAS  Google Scholar 

  50. Griesser H, Lennert K (1990) Bcl-2 gene rearrangements in malignant B-cell lymphomas. Br J Haematol 75: 142–143

    Article  PubMed  CAS  Google Scholar 

  51. Hickish TF, Purvies H, Mansi J et al (1991) Molecular monitoring of low grade non-Hodgkin’s lymphoma by gene amplification. Br J Cancer 64: 1161–1163

    Article  PubMed  CAS  Google Scholar 

  52. Yuan R, Dowling P, Zucca E et al (1993) Detection of bcl-2/JH rearrangement in follicular and diffuse lymphoma: concordant results of peripheral blood and bone marrow analysis at diagnosis. Br J Cancer 67: 922–925

    Article  PubMed  CAS  Google Scholar 

  53. West KP, Potter LJ, Henderson SD et al (1989) A retrospective study of follicular lymphomas. Histopathology 14: 629–636

    Article  PubMed  CAS  Google Scholar 

  54. Garvin AJ, Simon RM, Osborne CK et al (1983) An autopsy study of histologic progression in non-Hodgkin’s lymphomas. 192 cases from the National Cancer Institute. Cancer 52: 393–398

    Article  PubMed  CAS  Google Scholar 

  55. Zelenetz AD, Chen TT, Levy R (1991) Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B-cell. J Exp Med 173: 197–207

    Article  PubMed  CAS  Google Scholar 

  56. Gospodarowicz MK, Bush RS, Brown TC et al (1984) Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Rad Oncol Biol Phys 10: 489–497

    Article  CAS  Google Scholar 

  57. Leonard RCF, Hayward RL, Prescott RJ et al (1991) The identification of discrete prognostic groups in low grade non-Hodgkin’s lymphoma. Ann Oncol 2: 655–662

    PubMed  CAS  Google Scholar 

  58. Lepage E, Sebban C, Gisselbrecht C et al (1990) Treatment of low-grade non-Hodgkin’s lymphomas: assessment of doxorubicin in a controlled trial. Hematol Oncol 8: 31–39

    Article  PubMed  CAS  Google Scholar 

  59. Soubeyran P, Eghbali H, Bonichon F et al (1991) Low-grade follicular lymphomas: analysis of prognosis in a series of 281 patients. Eur J Cancer 27: 1606–1613

    Article  PubMed  CAS  Google Scholar 

  60. Romaguera JE, McLaughlin P, North L et al (1991) Multivariate analysis of prognostic factors in stage-IV follicular low-grade lymphoma: a risk model. J Clin Oncol 9: 762–769

    PubMed  CAS  Google Scholar 

  61. Paryani SB, Hoppe RT, Cox RS et al (1983) Analysis of non-Hodgkin’s lymphomas with nodular and favorable histologies, stages I and II. Cancer 52: 2300–2307

    Article  PubMed  CAS  Google Scholar 

  62. Steward WP, Crowther D, McWilliam LJ et al (1988) Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin’s lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer 61: 441–447

    Article  PubMed  CAS  Google Scholar 

  63. Bennett JM, Cain KC, Glick JH et al (1986) The significance of bone marrow involvement in non-Hodgkin’s lymphoma: the Eastern Cooperative Oncology Group experience. J Clin Oncol 4: 1462–1409

    PubMed  CAS  Google Scholar 

  64. Spinolo JA, Cabanillas F, Dixon DO et al (1991) Therapy of relapsed or refractory low-grade follicular lymphomas: factors associated with complete remission, survival and time to treatment failure. Ann Oncol 3: 227–232

    Google Scholar 

  65. Kantarjian HM, McLaughlin P, Fuller LM et al (1984) Follicular large cell lymphoma: analysis and prognostic factors in 62 patients. J Clin Oncol 2: 811–819

    PubMed  CAS  Google Scholar 

  66. McLaughlin P, Fuller LM, Velasquez WS et al (1986) Stage I—II follicular lymphoma. Treatment results for 76 patients. J Cancer 58: 1596–1602

    Article  CAS  Google Scholar 

  67. Gallagher CJ, Gregory WM, Jones AE et al (1986) Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 4: 1470–1480

    PubMed  CAS  Google Scholar 

  68. Litam P, Swan F, Cabanillas F (1991) Prognostic value of serum p2-microglobulin in low-grade lymphoma. Ann Intern Med 114: 855–860

    PubMed  CAS  Google Scholar 

  69. Coiffìer B, Gisselbrecht C, Vose JM et al (1991) Prognostic factors in aggressive malignant lymphomas. Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 9: 211–219

    PubMed  Google Scholar 

  70. Coiffier B, Lepage E (1989) Prognosis of aggressive lymphoma: a study of five prognostic models with patients included in the LNH-84 regimen. Blood 74: 558–564

    PubMed  CAS  Google Scholar 

  71. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329: 987–994

    Article  Google Scholar 

  72. Coiffier B, Bastion Y, Berger F, Felman P, Bryon PA (1993) Prognostic factors in follicular lymphomas. Semin Oncol 20 [Suppl 5]: 89–95

    PubMed  CAS  Google Scholar 

  73. Montserrat E, Lopez-Guillermo A, Rozman C (1993) B-cell low-grade malignant lymphomas. In: Lechner and Gadner (eds) Haematology Trends ’93. Schattauer, Vienna, pp 56–79

    Google Scholar 

  74. Dumont J, Asselain B, Weil M et al (1981) Evolution lointaine des lymphomes nodulaires. Devenir de 85 malades traités entre 1968 et 1975. Nouv Presse Med 10: 2261–2265

    PubMed  CAS  Google Scholar 

  75. Cabanillas F, Lee MS, McLaughlin P et al (1993) Polymerase chain reaction (PCR): an effective way of monitoring response in follicular lymphomas (FL). Proc Am Soc Clin Oncol 12: 365

    Google Scholar 

  76. Portlock CS (1990) Management of the low-grade non-Hodgkin’s lymphomas. Semin Oncol 17: 51–59

    PubMed  CAS  Google Scholar 

  77. Gomez GA, Barios M, Krishnamsetty RM et al (1986) Treatment of early - stage I and II - nodular poorly differentiated lymphocytic lymphoma. Am J Clin Oncol 9: 40–47

    Article  PubMed  CAS  Google Scholar 

  78. Lawrence TS, Urba WJ, Steinberg SM et al (1988) Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute. Int J Rad Oncol Biol Phys 14: 417–424

    Article  CAS  Google Scholar 

  79. Stetler-Stevenson M, Raffeld M, Cohen P et al (1988) Detection of occult follicular lymphoma by specific DNA amplification. Blood 72: 1822–1825

    CAS  Google Scholar 

  80. Portlock CS, Rosenberg SA (1979) No initial therapy for stage III and IV non-Hodgkin’s lymphomas of favorable histologic types. Ann Intern Med 90: 10–13

    PubMed  CAS  Google Scholar 

  81. Mead GM, Macbeth FR, Ryall RDH et al (1984) A report on a prospective trial of no initial therapy in patients with asymptomatic favourable prognosis non-Hodgkin’s lymphoma. Hematol Oncol 2: 179–188

    PubMed  CAS  Google Scholar 

  82. O’Brien MER, Easterbrook P, Powell J et al (1991) The natural history of low grade non-Hodgkin’s lymphoma and the impact of a no initial treatment policy on survival. Q J Med 80: 651–660

    PubMed  Google Scholar 

  83. Cadman E, Drislane F, Waldron JA et al (1982) High-dose pulse chlorambucil. Effective therapy for rapid remission induction in nodular lymphocytic poorly differentiated lymphoma. Cancer 50: 1037–1041

    Article  PubMed  CAS  Google Scholar 

  84. Portlock CS, Fisher DS, Cadman E et al (1987) High-dose pulse chlorambucil in advanced, low-grade non-Hodgkin’s lymphoma. Cancer Treat Rep 71: 1029–1031

    PubMed  CAS  Google Scholar 

  85. Case DC (1984) Comparison of M-2 protocol with COP in patients with nodular lymphoma. Oncology 41: 159–163

    Article  PubMed  Google Scholar 

  86. Hoppe RT, Kushlan P, Kaplan HS et al (1981) The treatment of advanced stage favorable histology non-Hodgkin’s lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy and whole body irradiation. Blood 58: 592–598

    PubMed  CAS  Google Scholar 

  87. Portlock CS, Rosenberg SA, Glatstein E et al (1976) Treatment of advanced non-Hodgkin’s lymphomas with favorable histologies: preliminary results of a prospective trial. Blood 47: 747–756

    PubMed  CAS  Google Scholar 

  88. Bagley CM, DeVita VT, Berard CW et al (1972) Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine and prednisone. Ann Intern Med 76: 227–234

    PubMed  Google Scholar 

  89. Jones SE, Grozea PN, Metz EN (1979) Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma. A Southwest Oncology Group study. Cancer 43: 417–425

    Article  PubMed  CAS  Google Scholar 

  90. Ezdinli EZ, Anderson JR, Melvin F et al (1985) Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol 3: 769–775

    PubMed  CAS  Google Scholar 

  91. Glick JH, Barnes JM, Ezdinli EZ et al (1981) Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood 58: 920–925

    PubMed  CAS  Google Scholar 

  92. Kalter S, Holmes L, Cabanillas F (1987) Long-term results of treatment of patients with follicular lymphomas. J Hematol Oncol 15: 127–138

    Google Scholar 

  93. McLaughlin P, Cabanillas F, Hagemeister FB et al (1993) CHOP-Bleo plus interferon for stage IV low-grade lymphoma. Ann Oncol 4: 205–211

    PubMed  CAS  Google Scholar 

  94. Smalley RV, Andersen JW, Hawkins MJ et al (1992) Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin’s lymphoma. N Engl J Med 327: 1336–1341

    Article  PubMed  CAS  Google Scholar 

  95. Solal-Céligny P, Lepage E, Brousse N et al (1993) Recombinant interferon-alfa-2b combined with doxorubicin-containing regimen in advanced follicular lymphoma patients. N Engl J Med 329: 1608–1614

    Article  PubMed  Google Scholar 

  96. Cheson BD (1992) New antimetabolites in the treatment of human malignancies. Sem Oncol 19: 695–706

    CAS  Google Scholar 

  97. Whelan JS, Davis CL, Rule S et al (1991) Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer 64: 120–123

    Article  PubMed  CAS  Google Scholar 

  98. Redman JR, Cabanillas F, Velasquez WS et al (1992) Phase-II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J Clin Oncol 10: 790–794

    PubMed  CAS  Google Scholar 

  99. Hachster H, Cassileth P (1990) Fludarabine phosphate therapy of non-Hodgkin’s lymphoma. Sem Oncol 17: 63–65

    Google Scholar 

  100. Fidler IJ, Heicappellz R, Saiki I et al Direct antiproliferative effects of recombinant human Interferon-α B/D hybrids on tumour cell lines. J Cancer Res 198: 2020–2027

    Google Scholar 

  101. Toy JL (1983) The interferons. Clin Exp Immunol 54: 1–13

    PubMed  CAS  Google Scholar 

  102. Gresser I (1985) How does interferon inhibit tumor growth? In: Gresser I (ed) Interferon. Academic, New York, pp 93–126

    Google Scholar 

  103. Borden EC (1979) Interferons, rationale for clinical trials in neoplastic disease. Ann Intern Med 91: 472–479

    PubMed  CAS  Google Scholar 

  104. Goldstein D, Laszlo J (1986) Interferon therapy in cancer: From imaginon to interferon. J Cancer Res 46: 4315–4329

    CAS  Google Scholar 

  105. Kirchner H (1984) Interferons - a group of multiple lymphokines. Semin Immunopathol 7: 347–374

    CAS  Google Scholar 

  106. Paulnock DM, Borden EC (1985) Modulation of immune functions by interferons. In: Reif AW, Mitchell M (eds) Immunity to cancer. Academic, New York, pp 545–559

    Google Scholar 

  107. Stewart WE, Blanchard DK (1985) Interferons: cytostatic and immunomodulatory effects. In: Reif AW, Mitchell M (eds) Immunity to cancer. Academic, New York, pp 295–307

    Google Scholar 

  108. Williams BRG, Fish EN (1985) Interferons and viruses: in vitro studies. In: Taylor-Papadimitriou J (ed) Interferons. Their impact in biology and medicine. Oxford University Press, Oxford, pp 40–60

    Google Scholar 

  109. Kirkwood JM, Ernstoff MS (1984) Interferons in the treatment of human cancer. J Clin Oncol 2: 336–352

    PubMed  CAS  Google Scholar 

  110. de Mel WCP, Hoffbrand AV, Giles FJ et al (1990) Alpha interferon therapy for haematological malignancies: correlation between in vivo induction of the 2’, 5’oligoadenylate system and clinical response. Br J Haematol 74: 452–456

    Article  PubMed  Google Scholar 

  111. Merigan TC, Sikora K, Breeden JH et al (1978) Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin’s lymphoma. N Engl J Med 299: 1449–1453

    Article  PubMed  CAS  Google Scholar 

  112. Louie AC, Gallagher JG, Sikora K et al (1981) Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin’s lymphoma. Blood 58: 712–718

    PubMed  CAS  Google Scholar 

  113. Gutterman JU, Blumenschein GR, Alexanian R et al (1980) Leukocyte interferon-induced tumour regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med 93: 399–406

    PubMed  CAS  Google Scholar 

  114. Horning S (1983) Lymphoma. In: Sikora K (ed) Interferon and Cancer. Plenum, New York, pp 777–783

    Google Scholar 

  115. Siegert W, Theml H, Fink U et al (1982) Treatment of non-Hodgkin’s lymphoma of low-grade malignancy with human fibroblast interferon. Anti Cancer Res 2: 193–198

    CAS  Google Scholar 

  116. Gallagher JG, Louie AC, Sikora K, Levy R, Merigan TC, Rosenberg SA (1982) Evaluation of human leukocyte interferon in patients with non-Hodgkin’s lymphoma and Hodgkin’s disease. In: Terry, Rosenberg SA (eds) Immunotherapy of human cancer. Elsevier North Holland, Amsterdam, pp 393–396

    Google Scholar 

  117. Kamihira S, Soda H, Kinoshita KI, Ichimaru M (1983) The effect of human lymphoblastoid interferon in adult T-cell leukaemia and non-Hodgkin’s lymphoma. Jap J Cancer Chemother 10: 2188–2193

    CAS  Google Scholar 

  118. Foon SA, Sherwin SA, Abrams PG et al (1984) Treatment of advanced non-Hodgkin’s lymphoma with recombinant leukocyte A interferon. N Engl J Med 311: 1148–1152

    Article  PubMed  CAS  Google Scholar 

  119. Sherwin SA, Knost JA, Fein S et al (1982) A multiple-dose phase I trial of recombinant leukocyte A interferon in cancer patients. JAMA 248: 2461–2466

    Article  PubMed  CAS  Google Scholar 

  120. Leavitt RD, Kaplan RS, Bonnern E et al (1985) High and low dose treatment for high and low grade non-Hodgkin’s lymphoma. In: Kisner D, Smyth JF (eds) Interferon alpha-2: Pre-clinical and clinical evaluation. Nijhoff, Boston, pp 57–73

    Google Scholar 

  121. O’Connell MJ, Colgan JP, Oken MM et al (1986) Clinical trial of recombinant leukocyte A interferon as initial therapy for favourable histology non-Hodgkin’s lymphomas and chronic lymphocytic leukaemia. An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 4: 128–136

    PubMed  Google Scholar 

  122. Wagstaff J, Loynds P, Crowther D et al (1986) A phase II study of human recombinant alpha-2 interferon in patients with low grade non-Hodgkin’s lymphoma. Cancer Chemother Pharmacol 18: 54–58

    Article  PubMed  CAS  Google Scholar 

  123. Steis RG, Föon KA, Longo DL (1987) Current and future uses of recombinant interferon alpha in the treatment of low-grade non-Hodgkin’s lymphoma. Cancer 59 [Suppl 1]: 658–663

    Article  PubMed  CAS  Google Scholar 

  124. Mantovani L, Guglielmi C, Martelli M, Lombardi A, Mandelli F (1988) Interferon in the treatment of non-Hodgkin’s lymphomas. Clinica Therapeutica 127: 123–130

    CAS  Google Scholar 

  125. Solal-Celigny Ph, Lepage E, Brousse N et al (1990) Interferon alfa-2b in patients with low tumor burden follicular non-Hodgkin’s lymphoma. Preliminary results from the “Groupe d’Etude des Lymphomes Folliculaires” (GELF, France and Belgium). Symposium Abstracts, International Cancer Update: Focus on Intron A, November 1990, Cannes

    Google Scholar 

  126. Chirigos MA, Pearson JW (1973) Cure of murine leukaemia with drug and interferon treatment. J Natl Cancer Inst 51: 1367

    PubMed  CAS  Google Scholar 

  127. Gresser I, Maury C, Tovey M et al (1978) Efficacy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice. Eur J Cancer 14: 97

    PubMed  CAS  Google Scholar 

  128. Slater LM, Wetzel MW, Cesario T (1982) Combined interferon-antimetabolite therapy of murine L1210 leukaemia. Cancer 48: 5–9

    Article  Google Scholar 

  129. Mowshowitz SL, Chin-Bow ST, Smith GD et al (1982) Interferon and Cis-DPP: combination chemotherapy for P388 leukaemia in CDFI mice. J Interferon Res 2: 587

    Article  PubMed  CAS  Google Scholar 

  130. Rohatiner AZS, Richards MA, Barrett MJ et al (1987) Chlorambucil and interferon for low grade non-Hodgkin’s lymphoma. Br J Cancer 55: 225–226

    Article  PubMed  CAS  Google Scholar 

  131. Price CGA, Rohatiner AZS, Steward W et al (1991) Interferon alfa-2b in addition to chlorambucil in the treatment of follicular lymphoma: preliminary results of a randomized trial in progress. Eur J Cancer 27 [Suppl 4]: S34-S36

    PubMed  Google Scholar 

  132. Peterson BA, Petroni G, Oken MM, Ozer H (1993) Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low grade lymphomas: a preliminary report of an intergroup trial (CALGB 8691 and EST 7486). Proc Am Soc Clin Oncol 12: 366 (abstract 1240)

    Google Scholar 

  133. P. Solal-Celigny on behalf of GELA (1994) Presentation at ist Meeting of the European Haematology Association, Brussels, 4 June 1994

    Google Scholar 

  134. Hagenbeek A, Carde P, Somers R et al on behalf of the EORTC Lymphoma Cooperative Group (1992) Maintenance of remission with human recombinant alpha-2 interferon (Roferon-A) in patients with stages III and IV low grade malignant non-Hodgkin’s lymphoma. Results from a prospective, randomised phase III clinical trial in 331 patients. Blood 80 [Suppl 1]: 74a (abstract 288)

    Google Scholar 

  135. Hiddemann W, Unterhalt M, Koch P, Nahler M, Herrmann R, van de Loo J (1991) Alpha interferon maintenance therapy in patients with low-grade non-Hodgkin’s lymphomas after cytoreductive chemotherapy with prednimustine and mitoxantrone. Eur J Cancer 11027 [Suppl 4]: S37-S39

    Google Scholar 

  136. Anderson JW, Smalley RV (1993) Interferon alfa plus chemotherapy for non-Hodgkin’s lymphoma: five-year follow-up. N Engl J Med 329: 1821–1822

    Article  Google Scholar 

  137. Chiesi T on behalf of the Non-Hodgkin’s Lymphoma Cooperative Study Group (1991) Randomized study of chlorambucil (CB) compared to interferon (alfa-2b) combined with CB in low-grade non-Hodgkin’s lymphoma: An interim report of a randomized study. Eur J Cancer 27 [Suppl 4]: S31-S33

    Google Scholar 

  138. Grossbard ML, Press OW, Appelbaum FR et al (1992) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80: 863–878

    PubMed  CAS  Google Scholar 

  139. Meeker TC, Lowder J, Maloney DG et al (1985) A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65: 1349–1363

    PubMed  CAS  Google Scholar 

  140. Maloney DG, Brown S, Czerwinski DK (1992) Monoclonal anti-idiotype antibody therapy of B-cell lymphoma. The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 80: 1502–1510

    PubMed  CAS  Google Scholar 

  141. Brown SL, Miller RA, Horning SJ et al (1989) Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 73: 651–661

    PubMed  CAS  Google Scholar 

  142. Kwak LW, Campbell MJ, Czerwinski DK et al (1992) Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327: 1209–1215

    Article  PubMed  CAS  Google Scholar 

  143. Parker BA, Vassos AB, Halpern SE (1990) Radioimmunotherapy of human B-cell lymphoma with Y-90-conjugated antiidiotype monoclonal antibody. Cancer Res 50: S1022–S1028

    Google Scholar 

  144. Press OW, Eary JF, Badger CC, et al (1989) Treatment of refractory non-Hodgkin’s lymphoma with radiolabeled MB-i (anti-CD37) antibody. J Clin Oncol 7: 1027–1038

    PubMed  CAS  Google Scholar 

  145. Kaminski MS, Zasadny KR, Francis IR et al (1993) Radioimmunotherapy of B-cell lymphoma with [I-i3i]anti-Bi (anti-CD2o) antibody, N Engl J Med 329: 459–465

    Article  PubMed  CAS  Google Scholar 

  146. Armitage JO (1993) Autologous bone marrow transplantation for patients with aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant 10: 62–63

    Google Scholar 

  147. Armitage JO (1993) Treatment of non-Hodgkin’s lymphoma. N Engl J Med J 328: 1023–1030

    Article  CAS  Google Scholar 

  148. Cheson BD, Lacerna L, Leyland-Jones B et al (1989) Autologous bone marrow transplantation. Current status and future directions. Ann Intern Med 110: 51–65

    PubMed  CAS  Google Scholar 

  149. Colombat P, Donadio D, Fouillard L et al (1993) Value of autologous bone marrow transplantation in follicular lymphoma. A France Autogreffe retrospective study of 42 patients. Bone Marrow Transplant

    Google Scholar 

  150. Freedman AS, Takvorian T, Anderson KC et al (1990) Autologous bone marrow transplantation in B-cell non-Hodgkin’s lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 8: 784–791

    PubMed  CAS  Google Scholar 

  151. Rohatiner AZS, Lister TA (1991) New approaches to the treatment of follicular lymphoma. Br J Haematol 79: 349–354

    Article  PubMed  CAS  Google Scholar 

  152. Campos L, Bastion Y, Roubi N et al (1993) Peripheral blood stem cell harvested after chemotherapy and GM-CSF for treatment intensification in patients with advanced lymphoproliferative diseases. Leukemia (in press)

    Google Scholar 

  153. Gribben JG, Freedman AS, Neuberg D (1991) Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325: 525–1533

    Article  Google Scholar 

  154. Gribben JG, Neuberg D, Freedman AS et al (1993) Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81: 3449–3457

    PubMed  CAS  Google Scholar 

  155. Price CGA, Meerabux J, Murtagh S et al (1991) The significance of circulating cells carrying t (14;18) in long remission from follicular lymphoma. J Clin Oncol 9: 1527–1532

    PubMed  CAS  Google Scholar 

  156. Greene MH, Young RC, Merrill JM, De Vita VT (1983) Evidence of a treatment-dose response in acute non-lymphocytic leukemias which occur after therapy of non-Hodgkin’s lymphoma. Cancer Res 43: 1891–1898

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. B. Coiffier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Giles
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Heinrich-Heine-Universität Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany

    Carlo Aul  & Wolfgang Schneider  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Coiffier, B., Berger, F., Giles, F. (1997). Follicular Lymphomas: Morphology, Prognostic Factors and Treatment. In: Aul, C., Schneider, W. (eds) Interferons. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60411-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60411-9_7

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-61051-9

  • Online ISBN: 978-3-642-60411-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation